Carvedilol
SIGMA/C3993 - ≥98% (HPLC), solid
Synonym: 1-
CAS Number: 72956-09-3
Empirical Formula (Hill Notation): C24H26N2O4
Molecular Weight: 406.47
MDL Number: MFCD00864692
Linear Formula: C24H26N2O4
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | solid |
| InChI | 1S/C24H26N2O4/c1-28-21-10 |
| InChI key | OGHNVEJMJSYVRP-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | OC(COC1=CC=CC2=C1C3=C(C=C |
| solubility | DMSO: >20 mg/mL |
| Application: | Carvedilol has been used: • as a β blocker to determine its effect on hypoxia inducible factor (HIF)-mediated erythropoiesis under hypoxia in vivo • as a βAR antagonist for inhibition of bARs • as a β-blocker to examine airway mechanics in fungus-challenged mice |
| Biochem/physiol Actions: | Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. |
| Biochem/physiol Actions: | Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality. |
| Features and Benefits: | This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 50, 250 mg in glass bottle |
| Symbol | GHS09 |
| Hazard statements | H411 |
| Precautionary statements | P273 |
| Hazard Codes | N |
| Risk Statements | 51/53 |
| Safety Statements | 61 |
| RIDADR | UN 3077 9 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |


